Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study by Herbert I. Hurwitz et al.
1 3
Cancer Chemother Pharmacol (2015) 75:851–859
DOI 10.1007/s00280-015-2709-8
ORIGINAL ARTICLE
Safety, pharmacokinetics, and pharmacodynamic properties 
of oral DEBIO1143 (AT‑406) in patients with advanced cancer: 
results of a first‑in‑man study
Herbert I. Hurwitz · David C. Smith · Henry C. Pitot · Jeffrey M. Brill · 
Rashmi Chugh · Elisabeth Rouits · Joseph Rubin · John Strickler · 
Gregoire Vuagniaux · J. Mel Sorensen · Claudio Zanna 
Received: 18 August 2014 / Accepted: 14 February 2015 / Published online: 27 February 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
Results Thirty-one patients received doses from 5 to 
900 mg. Only one DLT was reported at 180 mg. No MTD 
was found. Most common adverse drug reactions were 
fatigue (26 %), nausea (23 %), and vomiting (13 %). 
Average tmax and T1/2 was about 1 and 6 h, respectively. 
Exposure increased proportionally with doses from 80 to 
900 mg, without accumulation over 5 days. Plasma CCL2 
increased at 3–6 h postdose and epithelial apoptosis marker 
M30 on day 5; cIAP-1 levels in PBMCs decreased at all 
doses >80 mg. Five patients (17 %) had stable disease as 
the best treatment response.
Conclusion DEBIO1143 was well tolerated at doses up 
to 900 mg and elicited PD effects at doses greater 80 mg. 
Limited antitumor activity may suggest development rather 
as adjunct treatment.
Keywords IAP · Apoptosis · AT-406 · DEBIO1143 · 
Cancer · Resistance
Introduction
Inhibitors of apoptosis proteins (IAPs) may play a role in 
the development of cancer [1, 2]. Their over-expression 
has been linked not only to tumor growth and poor progno-
sis, but also to low treatment response or resistance [2, 4]. 
Therefore, the IAP protein family is generally considered 
a promising target for cancer drug development [2, 5, 6]. 
So far, six IAP antagonists have entered clinical develop-
ment [3]. One of these is DEBIO1143 (formerly AT-406, 
SM-406), a small molecule mimetic of second mitochon-
dria-derived activator of caspase (SMAC) [7].
In vitro studies have demonstrated DEBIO1143 to 
inhibit cell growth in various human cancer cell lines [2, 4] 
through binding of X-chromosome-linked IAP (XIAP) and 
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cellular IAPs 1 and 2 (cIAP-1 and -2). DEBIO1143 rap-
idly induced degradation of cIAP-1 in a cell-free functional 
assay [7] and apoptosis in xenograft tumors. Moreover, it 
was able to enhance the antitumoral effects of irradiation 
or various chemotherapeutic agents in multiple mouse can-
cer models [1, 4, 8]. Preclinical data further revealed good 
oral bioavailability in mice, rats, dogs, and non-human 
primates, enabling PK/PD modeling to predict tumor and 
plasma concentrations in humans [1].
Multiple high doses (40–120 mg/kg/day) induced hepa-
totoxicity in rats. In dogs, liver cell degeneration was 
seen at 3 and 10 mg/kg/day. In 4-week toxicology stud-
ies, the severely toxic dose (STD) in the rat was deter-
mined at 40 mg/kg and the highest non-severely toxic 
dose (HNSTD) in a non-rodent species at 1 mg/kg in dogs. 
Based on metabolism data and observed adverse events 
(AEs), the dog was considered the most relevant species, 
in line with reports on other IAP inhibitors [9]. The no 
observable adverse event level (NOAEL) of 1 mg/kg in 
dogs led to a calculated starting dose of 5 mg in humans. 
An intermittent dosing schedule was chosen to further miti-
gate the risk of unacceptable toxicity when entering clinical 
development.
The primary objective of this first-in-man study was to 
characterize the safety and determine the maximum tol-
erated dose (MTD) and schedule of DEBIO1143 when 
administered to patients with advanced solid tumors and 
lymphomas. Secondary objectives were to explore (a) PK 
of DEBIO1143, (b) any PD effects, (c) any observable anti-
tumor activity during the trial, and (d) its correlation with 
PK.
Materials and methods
Design
This was a multicenter, uncontrolled, open-label, dose-
escalation study on DEBIO1143 in patients with advanced 
cancer. It employed an accelerated titration design for dose 
escalation with 100 % dose increments in consecutively 
enrolled single patients until drug-related grade-2 toxicity 
was observed during the initial treatment cycle (until day 
28 or day 21 as per protocol amendment). If this was the 
case, cohort size was expanded to three patients and dos-
ing increment was reduced to 50 % of the last dose. Dose 
escalation was to be stopped at the MTD which was con-
sidered exceeded if at any dose level more than one patient 
experienced dose-limiting toxicity (DLT) during the first 
treatment cycle. DLT was defined as any of the follow-
ing: (a) non-hematological toxicity of grade ≥3 (excluding 
nausea, vomiting, diarrhea unless not controlled by maxi-
mal antiemetic/diarrheal therapy for >24 h); (b) anemia or 
neutropenia of grade ≥3 or thrombocytopenia of grade 4 or 
any grade if associated with clinically significant bleeding; 
(c) any AE resulting in dose delay or reduction; (d) any tox-
icity considered dose-limiting by the investigator. If only 
one out of the three patients of a cohort experienced drug-
related DLT, the cohort was expanded by another three 
patients to be treated at the same dose level. If none of 
these additional patients experienced DLT, the dose escala-
tion by 50 %, rounded down to the nearest capsule strength 
combination, continued in the next cohort of three patients.
Pharmacokinetic samples were taken from all patients 
on day 1 (predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 18 h postdose) 
and on day 5 (predose, 0.5, 1, 2, 3, 4, 6, 8 h postdose) of 
the first cycle. In addition, for exploratory PD analysis of 
IAP inhibition and activation of apoptosis, optional skin 
and tumor biopsies were taken from consenting patients on 
days 1 (predose) and 5 and blood samples on day 1 (pre-
dose, 1, 3, 6, 8, 12 h postdose), day 2 (predose), and day 5 
(3 h postdose).
The study was compliant with all applicable legal obli-
gations, the requirements of the Declaration of Helsinki 
and Good Clinical Practice. It was approved by the institu-
tional review boards of the three participating sites and reg-
istered under Clinicaltrials.gov (identifier: NCT01078649).
Patient population
Eligible were male and female adult outpatients with his-
tologically confirmed advanced or metastatic solid tumors 
or lymphoma for which no life prolonging or appro-
priate standard therapy was available. Patients had to 
be ambulatory (Eastern Cooperative Oncology Group 
(ECOG) performance status ≤1) with adequate hemato-
logical (ANC ≥1,500/mm3; hemoglobin >9.0 g/dL; plate-
let count ≥100,000/mm3), renal (creatinine ≤1.0 × upper 
limit of normal (ULN) or creatinine clearance of >60 ml/
min), hepatic (serum albumin ≥3.0 gm/dL; total bilirubin 
<1.0 × ULN; aminotransferases and alkaline phosphatase 
≤2.5 × ULN, including negative hepatitis testing), and car-
diac function without evidence of QTc prolongation.
As clinically significant bleeding formed part of the defi-
nition of DLT, further exclusion criteria were a history of 
gastrointestinal bleeding during the preceding year, of treat-
ment-requiring diabetes mellitus, or any condition associated 
with chronic inflammation (e.g., rheumatoid arthritis, inflam-
matory bowel disease, chronic infections) or affecting cop-
per accumulation or regulation (e.g., Wilson’s disease).
Last radiation and intake of steroids had to date back at 
least 14 days from study entry (thoracic radiation 28 days); 
patients had to be clinically stable and to have recovered to 
toxicity grade ≤1 from any prior cancer therapy. Patients had 
to have never received IAP inhibitors before. All patients had 
to give written informed consent to be enrolled in the trial.
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Treatment
Oral treatment had to be taken daily on days 1–5, initially 
every 14 days, later every 21 days as per protocol amend-
ment. The amendment was put in place to be more condu-
cive to future combination with common chemotherapy 
regimens and to reduce the potential for adverse drug 
reactions (ADRs) through an additional week of recovery 
between doses. The starting dose of 5 mg was increased 
in subsequent cohorts, based on DLT observed by the end 
of cycle 1. Stable or responding patients who experienced 
DLT were allowed to continue therapy at the next lower 
dose, once those had resolved to grade ≤1 within 2 weeks. 
End of treatment was triggered by disease progression, 
unacceptable toxicity, or withdrawal from the study for 
any reason. Cancer therapy other than DEBIO1143 was not 
allowed, but supportive care measures were. Concomitant 
treatment with aspirin at doses >81 mg/day or with any 
anticoagulants was prohibited.
Endpoints
Safety
The incidence of AE, ADR, and DLT was recorded at all 
scheduled visits (on days 1, 15, and 28 of each cycle and 
additionally on days 5, 8, and 22 of cycle 1) and graded 
according to the Common Terminology Criteria for 
Adverse Events, version 4.0 of the National Cancer Insti-
tute. Moreover, safety laboratory, 12-lead ECG, vital sign 
measurements, and physical examinations were performed.
Pharmacokinetics
Cmax and tmax were determined by direct assessment of the 
observed concentration versus time curves. The area under 
the curve until the last quantifiable concentration (AUC0−t) 
was estimated by a linear up/log down method if ≥3 val-
ues were available and extrapolated to infinity (AUCinf), 
if the extrapolated part was <30 %. The terminal elimina-
tion half-life (T1/2) was calculated as the ratio of loge2 to 
the apparent terminal phase rate constant (λz), determined 
through unweighted linear regression analysis on ≥3 log-
transformed concentrations on the linear portion of the ter-
minal slope, excluding the peak concentration. In general, 
points maximizing R2 up to at least 0.9 were included for 
linear regression.
Pharmacodynamics
cIAP-1 levels were measured in tumor tissue and surro-
gate tissue as available. Peripheral blood mononuclear cells 
(PBMCs) were analyzed for DEBIO1143-induced cIAP-1 
degradation. Plasma native cytokeratin-18 (M65) or cas-
pase-3 generated cytokeratin-18 fragments (M30), interleu-
kin 8 (IL8), chemokine ligand 2 (CCL2, MCP1), and tumor 
necrosis factor α (TNFα) were measured by ELISA as 
markers of epithelial cell death and inflammation on days 1 
(predose, 1, 3, 6, and 12 h postdose), 2, and 5.
Efficacy
Tumor evaluations were scheduled before therapy and after 
every other cycle of therapy. Changes were determined by 
physical examination, tumor markers, or standard imag-
ing techniques. Response to DEBIO1143 was assessed for 
solid tumors based on RECIST guidelines, version 1.1 [10] 
and for lymphoma as per the Revised Response Criteria 
for Malignant Lymphoma [11]. Read-outs were complete 
response (CR), partial response (PR), stable disease (SD), 
and disease progression (DP).
PK and PD analyses
DEBIO1143 plasma concentrations were measured using 
a validated LC–MS/MS assay. For the detection of cIAP-1 
in paraffin-embedded human tissue, a validated immuno-
histochemical (IHC) assay was used. DEBIO1143-induced 
cIAP-1 degradation was measured in PBMCs using West-
ern blot. Plasma biomarkers were measured through com-
mercial ELISAs. All laboratory analyses were performed 
by MPI Research, Inc. (PK) and Mosaic Laboratory, LLC 
(PD).
Data analysis
Descriptive statistics were presented as appropriate. Safety 
laboratory assessments, vital signs, body weight, ECOG, 
ECG, as well as PD and tumor response data were com-
pared over time to assess change from baseline during 
treatment and follow-up. In case of sufficient sample size, 
Wilcoxon matched pairs test was used for inferential com-
parisons. Data were analyzed using the Statistical Analysis 
System (SAS), version 9.1.3. Individual PK parameters 
were derived using WinNonlin (version 5.3, Pharsight 
Corp., Mountain View, CA).
Results
From March 30, 2010, until August 8, 2012, 31 patients, 
12 men (38.7 %) and 19 women (61.3 %) with a mean age 
of 52 ± 11 years, were enrolled and treated in 11 cohorts 
with oral DEBIO1143 doses ranging from 5 to 900 mg (5, 
10, 20, 40, 80, 120, 180, 260, 400, 600, 900 mg; Fig. 1). 
The great majority of patients were Caucasians (87.1 %; 
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one American Indian, one Asian, and two African-Amer-
ican) with metastatic solid tumors except one lymphoma 
patient. Most common were colorectal cancer in 14 patients 
(45.1 %), melanoma in three (9.7 %), and NSCLC in two 
(6.5 %); remaining tumor entities (38.7 %) were represented 
by one patient only (adrenal, angiosarcoma, appendiceal, 
breast, gastroesophageal, hemangiopericytoma, Hurthle cell, 
myoepithelial, ovarian, salivary gland, SCC penis).
Patients were treated with DEBIO1143 for up to 117 days 
and all patients completed at least one cycle; 2 cycles: 27 
(87.1 %) patients; 3 and 4 cycles: 5 (16.1 %) patients each; 
5 and 6 cycles: 2 (6.5 %) patients each; 7 and 8 cycles: one 
patient each (3.2 %) (Fig. 1; median 2 cycles). A drug-related 
grade 2 fatigue in a patient treated with 80 mg prompted 
expansion to 3-patient cohorts. Subsequently, a grade 3 
reversible ALT elevation in a patient receiving 180 mg was 
the only reported DLT which resulted in the expansion of this 
cohort to six patients. Dose was escalated to 900 mg daily 
before enrollment was halted due to the excessive number of 
pills to be taken. Thus, the MTD was not reached.
Safety
Of 31 patients in the safety population, 30 (96.8 %) expe-
rienced 242 AEs of which 82 (33.9 %) were considered 
related to study drug (ADRs). Most AEs were of mild 
to moderate severity and neither incidence nor severity 
increased with dose. The most affected organ systems were 
gastrointestinal, general, and skin and subcutaneous disor-
ders (Table 1) with fatigue, nausea, and vomiting as the most 
common treatment-related AE, each occurring in >10 % of 
patients (Suppl. 1). A total of eight patients (25.8 %) expe-
rienced 13 SAEs (constipation, intestinal obstruction, asthe-
nia, pain, cerebrovascular accident, cranial nerve disorder, 
urinary retention (once each); nausea, vomiting, dyspnoea 
(twice each)), none of which was considered related to 
study drug. No patient died during the study. Four (12.9 %) 
patients discontinued drug treatment due to AEs (ALT 
increase, cranial nerve disorder, abdominal pain, dyspnoea), 
of which only the ALT increase was considered related to 
study drug. This DLT was a fivefold, but asymptomatic 
ALT increase along with grade 2 elevations of other liver 
function tests after the first treatment cycle in a 57-year-old 
white female patient with metastatic colon cancer. ALT but 
not the other liver function tests had considerably decreased 
30 days posttreatment although metastatic disease in the 
liver may have been a contributing factor. ALT, AST, and 
GGT were within normal ranges in all remaining patients.
No clinically meaningful trends were seen in measure-
ments of safety laboratory, ECG, vital signs, body weight, 
Fig. 1  Patient flowchart accord-
ing to CONSORT. DP disease 
progression (second line: 
duration of stable disease); UPR 
upon patient request
Cohort 10
600 mg: N=3
Cohort 11
900 mg: N=6
Cohort 9 
400 mg: N=3
Cohort 8 
260 mg: N=3
Cohort 7
180 mg: N=6
Cohort 6 
120 mg: N=3
Cohort 5 
80 mg: N=3
Cohort 1-4 
5-40 mg: N=1
31 patients 
enrolled C1 C2 C3 C4 C5 C6
DP
DP
UPR
DP
DP
DP
197 days
DP
DLT
DP
DP
DP
DP
87 days
DP
134 days
DP
DP
85 days
DP
DP
93 days
DP
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or ECOG performance status. There were no dose reduc-
tions, delays, or modifications due to AEs or lack of 
tolerability.
Pharmacokinetics
DEBIO1143 drug levels at doses of ≥80 mg exceeded 
levels that have demonstrated activity in animal models. 
DEBIO1143 showed rapid absorption after oral intake with 
peak plasma concentrations within 1–3 h. Overall, increases 
in Cmax and AUC were proportional to doses ≥80 mg 
(Fig. 2). In general, PK disposition varied among individuals 
(Table 2), but mean T1/2 of DEBIO1143 on day 1 was consist-
ent [5.2–7.1 h] regardless of the dose. No evidence of drug 
accumulation was observed over the 5-day dosing period.
Pharmacodynamics
cIAP1 levels in tissues and PBMCs
A rapid and substantial cIAP1 degradation was observed in 
tumor or surrogate tissues. IHC staining of cIAP1 in skin 
biopsies of 12 patients revealed a trend for a decrease in 
the level of cIAP1 (Fig. 3a). In baseline and on-treatment 
tumor biopsies from two patients with melanoma, cIAP1 
was detected with intensities ranging from 0 to 2+. In the 
patient treated with DEBIO1143 at 120 mg/day, the immu-
noactivity of cIAP1 decreased from 150 (predose) to 130 
on day 5. By contrast, only negligible effect on the per-
centage of cIAP1-positive cells was observed in the tumor 
biopsies of the other melanoma patient treated at 400 mg/d.
The expression of cIAP1 was evaluable in PBMCs 
from 28 patients with doses above 80 mg using Western 
Table 1  Number of patients with ADRs and ADR frequency by system organ class
Dose cohort ≤40 mg 80 mg 120 mg 180 mg 260 mg 400 mg 600 mg 900 mg Total %
N 4 3 3 6 3 3 3 6 31 100
Gastrointestinal disorders 1 2 1 2 1 1 2 3 13 41.9
General disorders and administration site reactions 1 2 3 1 2 1 10 32.3
Skin and subcutaneous disorders 1 1 2 1 1 3 9 29.0
Metabolism and nutrition disorders 1 1 1 1 2 6 19.4
Musculoskeletal and connective tissue disorders 1 1 1 1 4 12.9
Nervous system disorders 1 1 1 3 9.7
Investigations 3 3 9.7
Respiratory, thorax, and mediastinum disorders 1 1 2 6.5
Eye disorders 1 1 3.2
Psychiatric disorders 1 1 3.2
Vascular disorders 1 1 3.2
Patients with any related AE 1 2 1 5 1 1 3 4 18 58.1
Fig. 2  Dose proportionality of Cmax and AUCinf
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Table 2  Pharmacokinetics of DEBIO1143, means (standard deviation)
ND not determined
** Median (minimum–maximum)
Dose 
(mg)
n Cmax (ng/mL) Tmax** (h) AUC0−t (ng*h/mL) AUC0−inf (ng*h/mL) T1/2 (h) Day 1:5 
ratio
Day 1 Day 5 Day 1 Day 5 Day 1 Day 5 Day 1 Day 5 Day 1 Day 5
5 1 6.69 18.5 3.0 1.6 19.6 43.4 ND ND ND ND ND
10 1 37.4 26.9 1.0 3.5 129 103 152 117 2.46 2.53 0.77
20 1 126 134 1.0 0.5 615 375 643 451 5.44 3.37 0.70
40 1 627 184 1.0 6.1 2140 1090 2300 ND 6.38 ND ND
80 3 1330 
(891)
1670 
(1310)
2.0 
(0.7–3.0)
2.0 
(0.6–2.0)
6390 
(5420)
5020 
(3450)
6660 
(5700)
5920 
(4270)
5.22 
(0.890)
2.69 
(0.593)
0.96 (0.13)
120 3 1650 
(217)
1190 
(432)
1.0 
(0.5–1.0)
2.0 
(1.0–3.0)
6890 
(1010)
5430 
(2570)
7460 
(1230)
6770 
(3460)
6.39 
(1.04)
2.61 
(0.505)
0.88 (0.36)
180 7 2130 
(1010)
2160 
(1550)
2.0 
(0.5–6.0)
2.0 
(0.5–6.0)
10,600 
(2990)
7210 
(3620)
11,400 
(3080)
9980 
(5150)
6.06 
(1.05)
4.14 
(1.72)
0.90 (0.45)
260 3 2890 
(1420)
2760 
(999)
3.0 
(1.0–3.0)
2.0 
(1.1–6.0)
16,300 
(5710)
10600 
(2910)
17,900 
(6260)
11,700 
(2520)
6.59 
(0.416)
3.29 
(0.573)
0.82 (0.14)
400 3 5280 
(2570)
5540 
(3370)
1.0 
(0.6–2.0)
0.5 
(0.5–2.0)
25,000 
(11,300)
20,100 
(11,700)
27,000 
(12,400)
26,500 
(15,200)
6.27 
(0.367)
3.70 
(0.390)
0.92 (0.19)
600 3 5780 
(1410)
7110 
(2140)
1.1 
(0.6–1.1)
1.0 
(0.5–1.1)
27,000 
(12,500)
20,200 
(7530)
28,700 
(13,400)
25,000 
(9090)
5.75 
(0.478)
3.54 
(1.67)
0.90 (0.21)
900 6 10,100 
(5600)
10,300 
(2710)
1.5 
(1.0–3.0)
1.5 
(1.0–3.0)
56,100 
(21,900)
36,900 
(8210)
61,500 
(23,500)
47,000 
(8550)
7.11 
(0.675)
3.15 
(0.408)
0.83 (0.25)
Fig. 3  Expression of cIAP. a 
in skin biopsies of 12 patients 
(H-scores; on the top). b in 
PBMC (quantitative Western 
blot results as % from baseline) 
across doses (on the bottom; for 
results per dose see Suppl. 2)
857Cancer Chemother Pharmacol (2015) 75:851–859 
1 3
blot (Fig. 3b; Suppl. 2). In 20 patients, cIAP1 was read-
ily detectable at baseline but undetectable or extremely 
low in eight patients. In all patients with detectable cIAP1, 
DEBIO1143 led to rapid and persistent cIAP1 degradation 
regardless of dose.
Plasma levels of TNFα, IL8, CCL2, and M30/M65
In total, 173 plasma samples from 25 patients were meas-
ured for TNFa, CCL2, and IL8, biomarkers mechanisti-
cally related to DEBIO1143. In 108 samples, TNFα was 
below the limit of detection; four out of five patients with 
detectable TNFα levels showed some increase postdose. 
CCL2 was detectable in 25 patients and increased in 14 
patients across all dose levels; however, CCL2 increased in 
five out of six patients dosed with 900 mg (mean increase 
45 %, range −6 to 54 %). Increases became significant 3 
and 6 h postdose (p < 0.0001, Fig. 4). By contrast, nei-
ther an increase in plasma IL8 nor any correlation with 
DEBIO1143 exposure was observed. Plasma level of M30 
increased significantly on day 5 (p < 0.0033; Fig. 4). How-
ever, no significant changes were found for M65 or for the 
M30:M65 ratio. None of the biomarkers showed any appar-
ent relationship to the treatment response.
Antitumor activity
No patient had a complete or partial response. One patient 
with metastatic melanoma with latero-cervical lymph node 
involvement showed an 11 % reduction in target lesion 
dimensions at 400 mg/day. Progression in the same nodes 
was noted after six cycles. Stable disease as best response 
was seen in five patients (16.1 %) for a median duration of 
93 days (range 85–197 days; Fig. 1). All these patients had 
different cancer types (Hurthle cell, melanoma, breast, rec-
tal, hemangiopericytoma).
Discussion
Several SMAC mimetic IAP antagonists have entered 
clinical development, including DEBIO1143 (formerly 
AT-406), HGS1029 (formerly AEG-40826), GDC-0917 
and -0152, LCL-161, and birinapant (TL-32711). The lat-
ter two compounds have entered phase II trials. Our results 
on DEBIO1143 add to the existing body of evidence from 
these clinical trials on SMAC mimetic IAP antagonists. In 
general, tolerability and safety of this class of drugs have 
been acceptable [12–14]. These trials have not revealed any 
consistent AE in humans [3, 12–14] except an increased 
incidence of Bell’s Palsy syndrome at higher doses of 
birinapant which can be prevented by dose titration in the 
initial treatment cycle [15]. In this regard, it is noteworthy 
that the cerebrovascular accident and cranial nerve disor-
der in our study were both unlikely related to DEBIO1143. 
The former occurred 23 days after last intake, and signs 
of thrombocytopenia, coagulopathy, or hypertension were 
absent during the two cycles of treatment as well as at the 
time of the event. By contrast, an occult metastasis could 
not be ruled out. The cranial nerve disorder was not Bell’s 
Palsy syndrome as it affected cranial nerve 5 rather than 
7; it was most consistent with progression of leptomenin-
geal disease. In general, there was no grade 4–5 treatment-
related AE at all, even during treatment for over 6 months. 
The only case of transient G3 hepatotoxicity is consistent 
Fig. 4  Pharmacodynamic measurements
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with preclinical data and linked to the mechanism of action 
of SMAC mimetic IAP inhibitors [16, 17].
Our PK data in humans confirmed drug exposures at or 
above those needed for activity in preclinical models [7]. 
PK disposition of DEBIO1143 is suitable for once daily 
dosing over 5 consecutive days every 3 weeks. DEBIO1143 
showed proportional plasma increases at doses >80 mg in 
our study (Fig. 2). However, beyond this threshold, neither 
PD nor antitumor activity showed any dose relationship, but 
all doses resulted in the degradation of cIAP-1 in PBMCs 
and at least in a trend for a decrease in cIAP levels in surro-
gate skin tissue. The on-target activity of DEBIO1143 was 
also supported by the significant increase in CCL2 plasma 
levels (Fig. 4), which might be a consequence of the cIAP-1 
degradation through modulation of NF-κB. CCL2, actually 
a marker of inflammation, has also been associated with the 
stimulation of a host antitumor response [18] which would 
be in line with the observed M30 increase indicating drug-
induced epithelial apoptosis [19].
However, interpretation of PD data remains limited due 
to the small samples sizes of dose groups and the lacking 
dose–response relationship. Our data also remain inconclu-
sive regarding a recommendable dose, although 900 mg/
day resulted in acceptable tolerability and in exposures 
with proven activity in preclinical experiments. It may thus 
serve at least as a starting dose for phase II. In addition, the 
modest clinical activity of IAP inhibitors shown in unse-
lected refractory cancer patients so far suggests the need 
for combination approaches and screening for more sensi-
tive subpopulations.
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